Kyowa Hakko Kirin Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Kyowa Hakko Kirin Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the Kyowa Hakko Kirin Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kyowa Hakko Kirin Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kyowa Hakko Kirin Co., Ltd.

The report provides overview of Kyowa Hakko Kirin Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Kyowa Hakko Kirin Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Kyowa Hakko Kirin Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kyowa Hakko Kirin Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kyowa Hakko Kirin Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kyowa Hakko Kirin Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Kyowa Hakko Kirin Co., Ltd. Snapshot 8

Kyowa Hakko Kirin Co., Ltd. Overview 8

Key Information 8

Key Facts 8

Kyowa Hakko Kirin Co., Ltd. - Research and Development Overview 9

Key Therapeutic Areas 9

Kyowa Hakko Kirin Co., Ltd. - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Pipeline Products - Out-Licensed Products 17

Out-Licensed Products/Combination Treatment Modalities 18

Kyowa Hakko Kirin Co., Ltd. - Pipeline Products Glance 19

Kyowa Hakko Kirin Co., Ltd. - Late Stage Pipeline Products 19

Pre-Registration Products/Combination Treatment Modalities 19

Phase III Products/Combination Treatment Modalities 20

Kyowa Hakko Kirin Co., Ltd. - Clinical Stage Pipeline Products 21

Phase II Products/Combination Treatment Modalities 21

Phase I Products/Combination Treatment Modalities 22

Kyowa Hakko Kirin Co., Ltd. - Early Stage Pipeline Products 23

Preclinical Products/Combination Treatment Modalities 23

Discovery Products/Combination Treatment Modalities 24

Kyowa Hakko Kirin Co., Ltd. - Drug Profiles 25

brodalumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

darbepoetin alfa 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

granisetron ER 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

romiplostim 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

tivozanib hydrochloride 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

benralizumab 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

burosumab 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

istradefylline 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

mogamulizumab 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

MT-4580 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

tivantinib 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

bardoxolone methyl 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

bleselumab 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

KHK-4083 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BIW-8962 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

antithrombin III (human) 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

entinostat 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

KHK-2823 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

KHK-2898 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

KHK-6640 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

CHKM-4927 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

K-685 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

K-756 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

KHK-KRAS 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

KHK-XXX 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

KM-2812 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Pr-1E11 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Z-3G1 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

K-777 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Small Molecules Targeting Protein-Protein Interactions for Undisclosed Indication 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Kyowa Hakko Kirin Co., Ltd. - Pipeline Analysis 76

Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Target 76

Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Route of Administration 78

Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Molecule Type 79

Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Mechanism of Action 80

Kyowa Hakko Kirin Co., Ltd. - Recent Pipeline Updates 82

Kyowa Hakko Kirin Co., Ltd. - Dormant Projects 115

Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products 116

Discontinued Pipeline Product Profiles 116

AGS-004 116

darbepoetin alfa 116

KHK-2866 117

KHK-6188 117

KRN-330 117

KRX-0601 117

KW-2449 117

KW-2450 117

KW-2478 118

KW-7158 118

litronesib 118

mogamulizumab 118

pibrozelesin hydrobromide 118

rocapuldencel-t 118

SAR-252067 119

tivantinib 119

tivozanib hydrochloride 119

Kyowa Hakko Kirin Co., Ltd. - Company Statement 120

Kyowa Hakko Kirin Co., Ltd. - Locations And Subsidiaries 121

Head Office 121

Other Locations & Subsidiaries 121

Appendix 124

Methodology 124

Coverage 124

Secondary Research 124

Primary Research 124

Expert Panel Validation 124

Contact Us 124

Disclaimer 125

List of Tables

List of Tables

Kyowa Hakko Kirin Co., Ltd., Key Information 8

Kyowa Hakko Kirin Co., Ltd., Key Facts 8

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Indication, 2016 10

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Stage of Development, 2016 13

Kyowa Hakko Kirin Co., Ltd. – Monotherapy Products in Pipeline, 2016 14

Kyowa Hakko Kirin Co., Ltd. – Partnered Products in Pipeline, 2016 15

Kyowa Hakko Kirin Co., Ltd. – Partnered Products/ Combination Treatment Modalities, 2016 16

Kyowa Hakko Kirin Co., Ltd. – Out-Licensed Products in Pipeline, 2016 17

Kyowa Hakko Kirin Co., Ltd. – Out-Licensed Products/ Combination Treatment Modalities, 2016 18

Kyowa Hakko Kirin Co., Ltd. – Pre-Registration, 2016 19

Kyowa Hakko Kirin Co., Ltd. – Phase III, 2016 20

Kyowa Hakko Kirin Co., Ltd. – Phase II, 2016 21

Kyowa Hakko Kirin Co., Ltd. – Phase I, 2016 22

Kyowa Hakko Kirin Co., Ltd. – Preclinical, 2016 23

Kyowa Hakko Kirin Co., Ltd. – Discovery, 2016 24

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Target, 2016 76

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Route of Administration, 2016 78

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Molecule Type, 2016 79

Kyowa Hakko Kirin Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 80

Kyowa Hakko Kirin Co., Ltd. – Recent Pipeline Updates, 2016 82

Kyowa Hakko Kirin Co., Ltd. – Dormant Developmental Projects,2016 115

Kyowa Hakko Kirin Co., Ltd. – Discontinued Pipeline Products, 2016 116

Kyowa Hakko Kirin Co., Ltd., Other Locations 121

Kyowa Hakko Kirin Co., Ltd., Subsidiaries 122

List of Figures

List of Figures

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Top 10 Indication, 2016 10

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Stage of Development, 2016 13

Kyowa Hakko Kirin Co., Ltd. – Monotherapy Products in Pipeline, 2016 14

Kyowa Hakko Kirin Co., Ltd. – Partnered Products in Pipeline, 2016 15

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Top 10 Target, 2016 76

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Route of Administration, 2016 78

Kyowa Hakko Kirin Co., Ltd. – Pipeline by Molecule Type, 2016 79

Kyowa Hakko Kirin Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 80

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports